Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the superiority of efficacy of TAK-438, once
daily (QD), to placebo in patients with non-erosive gastroesophageal reflux disease.